Lyell Immunopharma (NASDAQ:LYEL) Stock Price Target Lowered at HC Wainwright

Lyell Immunopharma (NASDAQ:LYEL) had its price target dropped by HC Wainwright from $45.00 to $39.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s price target points to a potential upside of 149.36% from the company’s current price.

A number of other brokerages also recently commented on LYEL. Royal Bank Of Canada set a $34.00 price target on shares of Lyell Immunopharma in a report on Friday, August 14th. Citigroup reissued a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, October 15th. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Sunday, October 25th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $44.00 target price on shares of Lyell Immunopharma in a report on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Lyell Immunopharma has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Lyell Immunopharma Price Performance

NASDAQ:LYEL opened at $15.64 on Friday. Lyell Immunopharma has a 1 year low of $7.20 and a 1 year high of $45.00. The stock’s 50 day simple moving average is $10.99 and its two-hundred day simple moving average is $16.46. The company has a market cap of $384.59 million, a price-to-earnings ratio of -1.25 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, November 4th. The company reported ($1.86) EPS for the quarter, beating analysts’ consensus estimates of ($2.01) by $0.15. Lyell Immunopharma had a negative return on equity of 107.62% and a negative net margin of 1,701,066.75%. The firm had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. As a group, analysts anticipate that Lyell Immunopharma will post -7.16 EPS for the current year.

Insider Transactions at Lyell Immunopharma

In related news, major shareholder Arch Venture Partners Ix, Llc purchased 2,321,262 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The stock was purchased at an average price of $10.77 per share, with a total value of $24,999,991.74. Following the completion of the purchase, the insider owned 3,747,790 shares of the company’s stock, valued at approximately $40,363,698.30. The trade was a 162.72% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Venture Fund Xiii L.P. Arch acquired 2,321,262 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The stock was purchased at an average price of $10.77 per share, with a total value of $24,999,991.74. Following the completion of the acquisition, the insider directly owned 3,747,790 shares of the company’s stock, valued at $40,363,698.30. This represents a 162.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 2,100 shares of company stock worth $28,757 over the last 90 days. Insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Lyell Immunopharma

Large investors have recently modified their holdings of the business. Ieq Capital LLC acquired a new stake in Lyell Immunopharma in the 3rd quarter worth approximately $102,000. Allspring Global Investments Holdings LLC grew its stake in Lyell Immunopharma by 4.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 16,824 shares of the company’s stock valued at $158,000 after purchasing an additional 679 shares during the last quarter. Walleye Capital LLC purchased a new stake in Lyell Immunopharma during the 1st quarter valued at about $445,000. Bank of New York Mellon Corp acquired a new position in shares of Lyell Immunopharma in the second quarter valued at about $347,000. Finally, Bank of America Corp DE increased its holdings in shares of Lyell Immunopharma by 314.2% in the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock valued at $668,000 after purchasing an additional 25,276 shares during the period. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells’ ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company’s investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient’s own immune cells, which are modified or selected and expanded before being administered as a potential treatment.